Search

Displaying results 1111 - 1120 of 2674 in total
  1. Drug

    Esomeprazole

    go.drugbank.com/drugs/DB00736
    ApprovedInvestigational

    [FDA Label] PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health.

  2. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas. … Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.

  3. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.

    Categories: Calcitonin Gene-Related Peptide Receptor Antagonists
  4. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    Simoctocog alfa is a recombinant B-domain deleted (BDD) rFVIII produced in genetically modified human embryonic kidney (HEK) 293F cells. The harvested product is concentrated and purified by a series of chromatography steps. It is an ant...

  5. Drug

    Liothyronine

    go.drugbank.com/drugs/DB00279
    ApprovedInvestigationalVet approved

    [T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]

  6. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand name Nexobrid [FDA

  7. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    Rurioctocog alfa pegol is a pegylated recombinant human coagulation factor VIII or antihemophilic factor. Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associa...

  8. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

  9. Drug

    Bictegravir

    go.drugbank.com/drugs/DB11799
    ApprovedInvestigational

    Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.

  10. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment

    Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator